394 results on '"Perrin, Christophe"'
Search Results
2. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
- Author
-
Jerusalem, Guy, Park, Yeon Hee, Yamashita, Toshinari, Hurvitz, Sara A, Modi, Shanu, Andre, Fabrice, Krop, Ian E, Farré, Xavier Gonzàlez, You, Benoit, Saura, Cristina, Kim, Sung-Bae, Osborne, Cynthia R, Murthy, Rashmi K, Gianni, Lorenzo, Takano, Toshimi, Liu, Yali, Cathcart, Jillian, Lee, Caleb, and Perrin, Christophe
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Breast Cancer ,Prevention ,Clinical Research ,Neurosciences ,Cancer ,Clinical Trials and Supportive Activities ,Humans ,Female ,Breast Neoplasms ,Receptor ,ErbB-2 ,Trastuzumab ,Immunoconjugates ,Camptothecin ,Brain Neoplasms ,Receptor ,erbB-2 ,Biochemistry and cell biology ,Oncology and carcinogenesis - Abstract
DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. In patients with BMs, the confirmed objective response rate (cORR) was 58.3% [95% confidence interval (CI), 36.6%-77.9%], and the median progression-free survival (mPFS) was 18.1 months (95% CI, 6.7-18.1 months). In patients without BMs (n = 160), cORR was 61.3% and mPFS was 16.4 months. Eight patients (47.1%) experienced a best overall intracranial response of partial response or complete response. Seven patients (41.2%) had a best percentage change in brain lesion diameter from baseline consistent with stable disease. Two patients (8.3%) with BMs and two (1.3%) without BMs experienced progression in the brain. The safety profile of T-DXd was consistent with previous studies. The durable clinical activity of T-DXd in this population warrants further investigation.SignificanceAdvances in treating HER2-positive metastatic breast cancer have greatly improved patient outcomes, but intracranial progression remains an important risk for which few therapeutic options are currently available. T-DXd demonstrated durable efficacy in patients with stable, treated BMs. This article is highlighted in the In This Issue feature, p. 2711.
- Published
- 2022
3. Prone position versus usual care in hypoxemic COVID-19 patients in medical wards: a randomised controlled trial
- Author
-
Nay, Mai-Anh, Hindre, Raphaël, Perrin, Christophe, Clément, Jérémy, Plantier, Laurent, Sève, Aymeric, Druelle, Sylvie, Morrier, Marine, Lainé, Jean-Baptiste, Colombain, Léa, Corvaisier, Grégory, Bizien, Nicolas, Pouget-Abadie, Xavier, Bigot, Adrien, Jamard, Simon, Nyamankolly, Elsa, Planquette, Benjamin, Fossat, Guillaume, and Boulain, Thierry
- Published
- 2023
- Full Text
- View/download PDF
4. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC
- Author
-
Kubicek, Pierre, Cesne, Axel Le, Lervat, Cyril, Toulmonde, Maud, Chevreau, Christine, Duffaud, Florence, Le Nail, Louis-Romée, Morelle, Magali, Gaspar, Nathalie, Vérité, Cécile, Castex, Marie-Pierre, Penel, Nicolas, Saada, Esma, Causeret, Sylvain, Bertucci, François, Perrin, Christophe, Bompas, Emmanuelle, Orbach, Daniel, Laurence, Valérie, Piperno-Neumann, Sophie, Anract, Philippe, Rios, Maria, Gentet, Jean-Claude, Mascard, Éric, Pannier, Stéphanie, Blouin, Pascale, Carrère, Sébastien, Chaigneau, Loïc, Soibinet-Oudot, Pauline, Corradini, Nadège, Boudou-Rouquette, Pascaline, Ruzic, Jean-Christophe, Lebrun-Ly, Valérie, Dubray-Longeras, Pascale, Varatharajah, Sharmini, Lebbe, Céleste, Ropars, Mickaël, Kurtz, Jean-Emmanuel, Guillemet, Cécile, Lotz, Jean-Pierre, Berchoud, Juliane, Cherrier, Grégory, Ducimetière, Françoise, Chemin, Claire, Italiano, Antoine, Honoré, Charles, Desandes, Emmanuel, Blay, Jean-Yves, Gouin, François, and Marec-Bérard, Perrine
- Published
- 2023
- Full Text
- View/download PDF
5. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- Author
-
Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, and Krop, Ian
- Subjects
Cancer ,Clinical Research ,Breast Cancer ,Clinical Trials and Supportive Activities ,6.2 Cellular and gene therapies ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Aged ,Aged ,80 and over ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Breast Neoplasms ,Camptothecin ,Consolidation Chemotherapy ,Female ,Humans ,Immunoconjugates ,Intention to Treat Analysis ,Kaplan-Meier Estimate ,Lung Diseases ,Interstitial ,Middle Aged ,Progression-Free Survival ,Receptor ,ErbB-2 ,Trastuzumab ,DESTINY-Breast01 Investigators ,Receptor ,erbB-2 ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundTrastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.MethodsIn this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety.ResultsOverall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%).ConclusionsTrastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).
- Published
- 2020
6. Real use of vehicle dynamic capacities: Motorcyclists versus motorists
- Author
-
Naude, Claire, Perrin, Christophe, and Serre, Thierry
- Published
- 2023
- Full Text
- View/download PDF
7. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
- Author
-
Frank, Sophie, Carton, Matthieu, Dubot, Coraline, Campone, Mario, Pistilli, Barbara, Dalenc, Florence, Mailliez, Audrey, Levy, Christelle, D’Hondt, Véronique, Debled, Marc, Vermeulin, Thomas, Coudert, Bruno, Perrin, Christophe, Gonçalves, Anthony, Uwer, Lionel, Ferrero, Jean-Marc, Eymard, Jean-Christophe, Petit, Thierry, Mouret-Reynier, Marie-Ange, Patsouris, Anne, Guesmia, Tahar, Bachelot, Thomas, Robain, Mathieu, and Cottu, Paul
- Published
- 2020
- Full Text
- View/download PDF
8. Plasma‐based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer
- Author
-
Corné, Julien, primary, Quillien, Véronique, additional, Godey, Florence, additional, Cherel, Mathilde, additional, Cochet, Agathe, additional, Le Du, Fanny, additional, Robert, Lucie, additional, Bourien, Héloïse, additional, Brunot, Angélique, additional, Crouzet, Laurence, additional, Perrin, Christophe, additional, Lefeuvre‐Plesse, Claudia, additional, Diéras, Véronique, additional, and De la Motte Rouge, Thibault, additional
- Published
- 2024
- Full Text
- View/download PDF
9. Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients
- Author
-
Corné, Julien, Le Du, Fanny, Quillien, Véronique, Godey, Florence, Robert, Lucie, Bourien, Héloïse, Brunot, Angélique, Crouzet, Laurence, Perrin, Christophe, Lefeuvre-Plesse, Claudia, Diéras, Véronique, and De la Motte Rouge, Thibault
- Published
- 2021
- Full Text
- View/download PDF
10. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- Author
-
Bouzid, Kamel, Campone, Mario, Coudert, Bruno, Nowecki, Zbigniew, Errihani, Hassan, Dalenc, Florence, Ferreira, Ana, Mano, Max, Ricci, Francesco, Kalofonos, Haralabos, Andreetta, Claudia, Montemurro, Filippo, Barrett, Sophie, Zhang, Qingyuan, Mavroudis, Dimitris, Matus, Juan, Beato, Carlos, Hu, Xichun, Gaafar, Rabab, Abdel Azeem, Hamdy, Perrin, Christophe, Ettl, Johannes, Lang, Istvan, Verma, Sunil, Li, Huiping, Brain, Etienne, Hoffmann, Oliver, Cariello, Anna, Tondini, Carlo, Altwegeiri, Taher, Loman, Niklas, Lux, Michael, Frassoldati, Antonio, Aziz, Zeba, Salas, Fernando, Streb, Joanna, Wronski, Andrzej, Menjón Beltrán, Salomón, Cicin, Irfan, Schmid, Peter, Laing, Robert, Tong, Zhongsheng, Boer, Katalin, Juhasz, Balazs, Gianni, Luca, Curigliano, Giuseppe, Juarez, Alejandro, Susnjar, Snezana, Matos, Erika, Uslu, Ruchan, Wildiers, Hans, Cruz, Marcelo, Bourgeois, Hugues, von Schumann, Raquel, Stemmer, Salomón, Vásquez, Flavia Morales, Dominguez, Adriana, Wojtukiewicz, Marek, Trifunovic, Jasna, Illarramendi, Jose Juan, Garcia, Laura, Peron, Yann Izarzugaza, Echarri, Maria Jose, Voitko, Natliia, Wheatley, Duncan, Waters, Simon, De Boer, Richard, Jerusalem, Guy, Cocquyt, Véronique, Barrios, Carlos, Panasci, Lawrence, Mattson, Johanna, Tanner, Minna, Gozy, Michel, Vasilopoulos, Georgios, Revesz, Janos, Latini, Luciano, Gridelli, Cesare, Lazaro, Jesus, Gonzalez, Antonio, Barnadas Molins, Agusti, Martinez, Eduardo, Alarcón, Jesús, Arance, Ana, Klint, Leif, Kovalyov, Oleksiy, Baird, Richard, Yeo, Belinda, McCarthy, Nicole, Greil, Richard, Wang, Shusen, Artignan, Xavier, Augereau, Paule, Juhasz-Boess, Ingolf, Ngan, Roger, Goldberg, Hadassah, Di Costanzo, Francesco, Ferraù, Francesco, Aleknavicius, Eduardas, Rashid, Kamran, Costa, Luís, Angel Garcia, Jose, de la Cruz, Luis Ruiz, López López, Rafael, Del Val, Olga, Ozyilkan, Ozgur, Azribi, Fathi, Verrill, Mark, Turner, Nicholas, Beith, Jane, Petzer, Andreas, Andrade, Jurandyr, Bernstein, Vanessa, Rayson, Daniel, Saad Eldin, Ibtessam, Achille, Mihaëla, Mueller, Volkmar, Gennari, Alessandra, Cascinu, Stefano, Ghosn, Marwan, El-Saghir, Nagi, Van den Bosch, Joan, Oosterkamp, Rianne, Kukulska, Monika, Pelaez, Ignacio, Hernandez, Carolina, del Mar Gordon, Maria, Dalmau, Elsa, Alonso, Jose Luis, Aksoy, Sercan, Coskun, Hasan Senol, Shparyk, Yaroslav, Varughese, Mohini, Panwar, Udaiveer, Barraclough, Lisa, Levitt, Nicola, Hicks, Jonathan, Rigg, Anna, Allen, Mark, Castillo, Cecila, Fein, Luis Enrique, Stuart-Harris, Robin, Singer, Christian, Stoeger, Herbert, Smiljanic, Sasha, Feng, Jifeng, Cedeño, Miguel, Berdah, Jean Francois, Orfeuvre, Hubert, Goncalves, Anthony, Grischke, Eva-Maria, Simon, Eike, Wagner, Steffen, Efremidou, Anna, Papazisis, Konstantinos, Evron, Ella, Inbar, Moshe, Baruch, Noa Ben, Geffen, David, Karminsky, Natalya, Ruggeri, Enzo Maria, Luigi, Cavanna, Grasso, Donatella, Juozaityte, Elona, Rafael Rodriguez Cid, Jeronimo, Roerdink, Henk, Siddiqi, Neelum, Passos Coelho, José Luís, Garre, Elisa Garcia, Garcia, Andres, Martínez Jañez, Noelia, Lopez Ceballos, Maria Helena, Mele, Mireia, García, María, Arcediano, Alberto, McAdam, Karen, Perren, Timothy, Taylor, Wendy, Humphreys, Alison, Vera, Raul, Kaen, Luis Alberto, Steger, Günther, Andel, Johannes, de Grève, Jacques, Huizing, Manon, Hegg, Roberto, Joy, Anil, Sehdev, Sandeep, Kütner, Riina, Ruohola, Johanna, Dohollou, Nadine, Grosjean, Jessica, Laplaige, Philippe, Largillier, Rémy, Martin, Philippe, Pottier, Virginie, Alexandre, Jerome, Christensen, Bernd, Zahm, Dirk-Michael, Khandan, Fariba, Lueck, Hans-Joachim, Fountzilas, Georgios, Fried, Georgeta, Giacobino, Alice, Bonetti, Andrea, Guerra, Yanin Chavarri, Van Warmerdam, Laurens, Van der Velden, Annette, Vrijaldenhoven, Suzan, de Jongh, Felix, Cavero, Milagros, Andres Conejero, Raquel, Murias, Adolfo, Saura, Salvador, Oltra, Amparo, Redondo, Andres, Ribelles, Nuria, Bachmeier, Kilian, Joffe, Johnathan, Chakraborti, Prabir, Beresford, Mark, Butt, Mohammad, Poole, Christopher, Yordi, Gassan, Woodward, Natasha, Amorim, Gilberto, Califaretti, Nadia, Fox, Susan, Robidoux, Andre, Li, NanLi, Li, Nenxiao, Jiang, Jun, Soria, Tannia, Padrik, Peeter, Saarni, Outi, Genet, Dominique, Catala, Stéphanie, Barletta, Hugues, Teixeira, Luis, Facchini, Thomas, Hesse, Tobias, Kühn, Thorsten, Ober, Angelika, Repp, Roland, Schroeder, Willibald, Pectasides, Dimitrios, Bodoky, Gyorgy, Kahan, Zsuzsanna, Jiveliouk, Irina, Rosengarten, Ora, Alabiso, Oscar, Perez, Mario, Van de Wouw, Yes, Smok-Kalwat, Jolanta, Damasceno, Margarida, Sousa, Gabriela, Abulkhair, Omalkhair, Antón Torres, Antonio, Martinez, Maria Purificación, Garcia Mata, Jesús, Jesús Florián Jerico, Marta Santisteban, Llombart, Antonio, Sanchez, Rosa, Torrego, Juan Carlos, Garate, Clara Olier, Rodriguez, Cesar, Llorente, Rosa, de Prado, Diego Soto, Cortés, Javier, Llorca, Cristina, Galán, Antonio, Viñas Villaro, Gemma, Narbe, Ulrik, Bjömeklett, Helena Granstam, Westwell, Sarah, Newby, Jackie, Jafri, Mariam, Rodríguez, Robinson, Alonso, Isabel, Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., Paluch-Shimon, S., Wardley, A., Merot, J.-L., du Toit, Y., Easton, V., Lindegger, N., and Miles, D.
- Published
- 2019
- Full Text
- View/download PDF
11. Real use of vehicle dynamic capacities: Motorcyclists versus motorists
- Author
-
Naude, Claire, primary, Perrin, Christophe, additional, and Serre, Thierry, additional
- Published
- 2023
- Full Text
- View/download PDF
12. Perineurioma - Two cases
- Author
-
Baran, Robert and Perrin, Christophe
- Published
- 2002
13. Patterns of care and outcome of CIC ‐rearranged sarcoma patients: A nationwide study of the French sarcoma group
- Author
-
Brahmi, Mehdi, primary, Gaspar, Nathalie, additional, Gantzer, Justine, additional, Toulmonde, Maud, additional, Boudou‐Rouquette, Pascaline, additional, Bompas, emmanuelle, additional, Firmin, Nelly, additional, Valentin, Thibaud, additional, Cancel, Mathilde, additional, Duffaud, Florence, additional, Bertucci, Francois, additional, Perrin, Christophe, additional, Dufresne, Armelle, additional, Marec‐Bérard, Perrine, additional, Jean‐Denis, Myriam, additional, Ray‐Coquard, Isabelle, additional, Le Loarer, Francois, additional, Pierron, Gaille, additional, Tirode, Franck, additional, Blay, Jean‐Yves, additional, and Watson, Sarah, additional
- Published
- 2022
- Full Text
- View/download PDF
14. Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies
- Author
-
Debieuvre, Didier, primary, Molinier, Olivier, additional, Falchero, Lionel, additional, Locher, Chrystèle, additional, Templement-Grangerat, Dorine, additional, Meyer, Nicolas, additional, Morel, Hugues, additional, Duval, Yannick, additional, Asselain, Bernard, additional, Letierce, Alexia, additional, Trédaniel, Jean, additional, Auliac, Jean-Bernard, additional, Bylicki, Olivier, additional, Moreau, Lionel, additional, Fore, Mathieu, additional, Corre, Romain, additional, Couraud, Sébastien, additional, Cortot, Alexis, additional, Freijat, Faraj Al, additional, Sheikh, Waad Al, additional, Alizon, Claire, additional, Amrane, Karim, additional, Auvray, Etienne, additional, Banciu, Nicolae, additional, Bedossa, Alexandra, additional, Belhaj, Issam, additional, Belle, Antoine, additional, Belmont, Laure, additional, Benmammar, Kheir Eddine, additional, Bernardi, Marie, additional, Beynel, Pascal, additional, Bigot, Fréderic, additional, Bizieux-Thaminy, Acya, additional, Blanchet-Legens, Anne-Sophie, additional, Bonnefoy, Philippe, additional, Bordier, Soraya, additional, Bravard, Anne-Sophie, additional, Briens, Éric, additional, Brun, Philippe, additional, Bugnet, Anne-Sophie, additional, Chablais, Laetitia, additional, Chiappa, Anne-Marie, additional, Chikouche, Reda, additional, Christiann, François, additional, Clarot, Caroline, additional, Courdeau-Labourie, Joelle, additional, Crequit, Jacky, additional, Dayen, Charles, additional, De chabot, Gonzague, additional, Debieuvre, Didier, additional, Decroisette, Chantal, additional, Dehette, Stéphanie, additional, Delafosse, Christian, additional, Delclaux, Bertrand, additional, Delmas, Christina, additional, Demontrond, Pierre, additional, Dot, Jean-Marc, additional, Dujon, Cécile, additional, Dumont, Patrick, additional, Dussopt, Christine, additional, Duval, Fatima, additional, Khanjari, Fethi El, additional, Fouet, Kevin, additional, Francois, Hugues, additional, Ghalloussi-Tebai, Yannick, additional, Goarant, Éric, additional, Godbert, Benoît, additional, Goupil, François, additional, Haouachi, Rym, additional, Hauss, Pierre-Alexandre, additional, Jaafar, Mohamad, additional, Jarjour, Baihas, additional, Jeandeau, Serge, additional, Julien, Sylvie, additional, Kraemer, Jean Philippe, additional, Kuntz, Pierre, additional, Lamotte, Florence, additional, Larive, Sébastien, additional, Laurent, Thomas, additional, Floch, Hervé Le, additional, Garff, Gwenaëlle Le, additional, Treut, Jacques Le, additional, Lecuyer, Emmanuelle, additional, Lefoll, Christine, additional, Leleu, Olivier, additional, Doubliez, Marguerite Lepoulain, additional, Levrat, Virginie, additional, Loutski-Vettese, Sandrine, additional, Maetz, Edith, additional, Magne, Fanny, additional, Maincent, Cécile, additional, Mairovitz, Alexa, additional, Marichy, Catherine, additional, Marion, Nancy, additional, Marquette, David, additional, Martignac, Bénédicte, additional, Martinez, Stéphanie, additional, Marty, Clothilde, additional, Masson, Philippe, additional, Maurer, Cyril, additional, Meniai, Vincent, additional, De Faverges, Geoffroy Milliet, additional, Monnet, Isabelle, additional, Mosser, Laurent, additional, Neidhardt, Anne-Catherine, additional, Nunes, David, additional, Obert, Julie, additional, Pante, Vanessa, additional, Paysse, Magalie, additional, Pegliasco, Herve, additional, Peloni, Jean-Michel, additional, Perrin, Christophe, additional, Petit, Lidia, additional, Picaud, Marjorie, additional, Pinsolle, Julian, additional, Popa, Mihai, additional, Portel, Laurent, additional, Quieffin, Jean, additional, Rabut, Hong, additional, Redureau, Élise, additional, Renault, David, additional, Renault, Patrick Aldo, additional, Rizzo, Claudia, additional, Russier, Maud, additional, Sabatini, Marielle, additional, Saelens, Thierry, additional, Schneider, Sophie, additional, Slaouti, Philippe, additional, Stoven, Luc, additional, Tack, Vincent, additional, Tavernier, Jean-Yves, additional, Thirard, Laurence, additional, Thomassin, Séverine, additional, Tiercin, Marie, additional, Tredaniel, Jean, additional, Tudor, Andreea, additional, Turlotte, Amélie, additional, Vincent, Colette, additional, and Virally, Jérôme, additional
- Published
- 2022
- Full Text
- View/download PDF
15. Additional file 1 of Prone position versus usual care in hypoxemic COVID-19 patients in medical wards: a randomised controlled trial
- Author
-
Nay, Mai-Anh, Hindre, Raphaël, Perrin, Christophe, Clément, Jérémy, Plantier, Laurent, Sève, Aymeric, Druelle, Sylvie, Morrier, Marine, Lainé, Jean-Baptiste, Colombain, Léa, Corvaisier, Grégory, Bizien, Nicolas, Pouget-Abadie, Xavier, Bigot, Adrien, Jamard, Simon, Nyamankolly, Elsa, Planquette, Benjamin, Fossat, Guillaume, and Boulain, Thierry
- Abstract
Additional file 1. Protocol.
- Published
- 2023
- Full Text
- View/download PDF
16. Additional file 2 of Prone position versus usual care in hypoxemic COVID-19 patients in medical wards: a randomised controlled trial
- Author
-
Nay, Mai-Anh, Hindre, Raphaël, Perrin, Christophe, Clément, Jérémy, Plantier, Laurent, Sève, Aymeric, Druelle, Sylvie, Morrier, Marine, Lainé, Jean-Baptiste, Colombain, Léa, Corvaisier, Grégory, Bizien, Nicolas, Pouget-Abadie, Xavier, Bigot, Adrien, Jamard, Simon, Nyamankolly, Elsa, Planquette, Benjamin, Fossat, Guillaume, and Boulain, Thierry
- Abstract
Additional file 2. Supplementary files.
- Published
- 2023
- Full Text
- View/download PDF
17. Does awake prone positioning prevent the use of mechanical respiratory support or death in COVID-19 patients on standard oxygen therapy hospitalised in general wards? A multicentre randomised controlled trial: the PROVID-19 protocol
- Author
-
Nay, Mai-Anh, primary, Planquette, Benjamin, additional, Perrin, Christophe, additional, Clément, Jérémy, additional, Plantier, Laurent, additional, Sève, Aymeric, additional, Druelle, Sylvie, additional, Morrier, Marine, additional, Lainé, Jean-Baptiste, additional, Colombain, Léa, additional, Corvaisier, Grégory, additional, Bizien, Nicolas, additional, Pouget-Abadie, Xavier, additional, Bigot, Adrien, additional, Bernard, Louis, additional, Nyamankolly, Elsa, additional, Fossat, Guillaume, additional, and Boulain, Thierry, additional
- Published
- 2022
- Full Text
- View/download PDF
18. Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens
- Author
-
Cywes-Bentley, Colette, Skurnik, David, Zaidi, Tanweer, Roux, Damien, Deoliveira, Rosane B., Garrett, Wendy S., Lu, Xi, O'Malley, Jennifer, Kinzel, Kathryn, Zaidi, Tauqeer, Rey, Astrid, Perrin, Christophe, Fichorova, Raina N., Kayatani, Alexander K. K., Maira-Litràn, Tomas, Gening, Marina L., Tsvetkov, Yury E., Nifantiev, Nikolay E., Bakaletz, Lauren O., Pelton, Stephen I., Golenbock, Douglas T., and Pier, Gerald B.
- Published
- 2013
19. Patterns of care and outcome of CIC‐rearranged sarcoma patients: A nationwide study of the French sarcoma group.
- Author
-
Brahmi, Mehdi, Gaspar, Nathalie, Gantzer, Justine, Toulmonde, Maud, Boudou‐Rouquette, Pascaline, Bompas, emmanuelle, Firmin, Nelly, Valentin, Thibaud, Cancel, Mathilde, Duffaud, Florence, Bertucci, Francois, Perrin, Christophe, Dufresne, Armelle, Marec‐Bérard, Perrine, Jean‐Denis, Myriam, Ray‐Coquard, Isabelle, Le Loarer, Francois, Pierron, Gaille, Tirode, Franck, and Blay, Jean‐Yves
- Subjects
EWING'S sarcoma ,SARCOMA ,LOG-rank test ,DATABASES ,DIAGNOSIS ,DISEASE remission - Abstract
Background: CIC‐rearranged sarcomas (CIC‐RS) represent the most frequent subset of "Ewing‐like" undifferentiated small round cell sarcomas. These tumors tend to be more aggressive than Ewing sarcomas. Moreover, treatment strategy can differ according to teams. The primary aim of this retrospective study was to describe the characteristics, treatments, and outcome for patients with CIC‐RS included in the French NETSARC+ database. Methods: Pediatric and adult patients from 13 French centers with a diagnosis of CIC‐RS were registered from October 2008 to March 2021. Patients and tumors characteristics were collected from the national network NETSARC+ database (http://netsarc.sarcomabcb.org). CIC‐RS diagnosis was pathologically and molecularly confirmed with a central review by expert pathologists. Two groups of patients were studied: those treated as classical Ewing sarcomas (cohort EwS) and those treated as high‐grade soft tissue sarcomas (cohort STS) according to ESMO and/or EpSSG guidelines. Survival was calculated using the Kaplan–Meier method and the log‐rank test was used to compare survival. Results: Among 79 patients, the male/female sex ratio was 0.7 and the median age at diagnosis was 27 years (range 2–87). With a median follow‐up of 37 months, 39 patients died of the disease. Median overall survival from diagnosis was 18 months, with no significant difference between both cohorts (p = 0.9). Nevertheless, when focusing on patients with metastatic disease at diagnosis (N = 21), all patients from cohort STS died of disease while some patients from cohort EwS were still alive and in complete remission. Conclusion: FSG experience confirms the aggressive clinical course of CDS patients regardless of chemotherapy regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study
- Author
-
Perrin, Christophe, primary, Athersuch, Katy, additional, Elder, Greg, additional, Martin, Manuel, additional, and Alsalhani, Alain, additional
- Published
- 2022
- Full Text
- View/download PDF
21. COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome
- Author
-
Dietz, Matthieu, Chironi, Gilles, Claessens, Yann-Erick, Farhad, Ryan Lukas, Rouquette, Isabelle, Serrano, Benjamin, Nataf, Valérie, Hugonnet, Florent, Paulmier, Benoît, Berthier, Frédéric, Keita-Perse, Olivia, Giammarile, Francesco, Perrin, Christophe, Faraggi, Marc, Fissore-Magdelein, C., Gabriel-Solean, S., Dahmani, B., Riss, I., Sorlin, P., Dupasquier, V., Pathak, A., Dugourd, C., Nicolai, M., Rijo, N., Beau, N., Magdelein, X., Olyve, F., Chaillou-Orpitz, S., Lépine, J., Lorillou, M., Maincent, C., Bertrand, S., Brunner, P., Dittlot, C., Fuerxer, F., Liberatore, M., Armando, G., Bouregba, M., Catineau, J., Garcia, P., and Tran, D.
- Subjects
Male ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Glucose uptake ,Inflammation ,Gastroenterology ,Fluorodeoxyglucose F18 ,Positron Emission Tomography Computed Tomography ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Lung ,Aged ,Aged, 80 and over ,business.industry ,COVID-19 ,Heart ,General Medicine ,Middle Aged ,medicine.disease ,FDG PET/CT ,Pneumonia ,Treatment Outcome ,medicine.anatomical_structure ,Radiology Nuclear Medicine and imaging ,Anaerobic glycolysis ,Original Article ,Female ,Lymph Nodes ,Lymph ,Bone marrow ,Radiopharmaceuticals ,medicine.symptom ,business - Abstract
Purpose [18F]-2-Fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with an increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes, and granulocytes. The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19. Methods Patients admitted with COVID-19 were prospectively enrolled. FDG PET/CT was performed from day 6 to day 14 of the onset of symptoms. Depending on FDG PET/CT findings, patients’ profiles were classified as “inflammatory” or “low inflammatory.” FDG PET/CT data were compared with chest CT evolution and short-term clinical outcome. All inflammatory sites were reported to screen potential extra-pulmonary tropism. Results Thirteen patients were included. Maximum standardized uptake values ranged from 4.7 to 16.3 in lungs. All patients demonstrated increased mediastinal lymph nodes glucose uptake. Three patients (23%) presented mild nasopharyngeal, two patients (15%) bone marrow, and five patients (38%) splenic mild increase in glucose uptake. No patient had significant digestive focal or segmental glucose uptake. There was no significant physiological myocardial glucose uptake in all patients except one. There was no correlation between PET lung inflammatory status and chest CT evolution or short-term clinical outcome. Conclusion Inflammatory process at the presumed peak of the inflammatory phase in COVID-19 patients is obvious in FDG PET/CT scans. Glucose uptake is heterogeneous and typically focused on lungs. Trial registration NCT04441489. Registered 22 June 2020 (retrospectively registered). Electronic supplementary material The online version of this article (10.1007/s00259-020-04968-8) contains supplementary material, which is available to authorized users.
- Published
- 2020
22. Livrable L5 - Nouveaux critères dynamiques de détection d'incidents pour les 2RM et analyse de l'utilisation réelle des capacités dynamiques d'un 2RM - Projet DYMOA
- Author
-
Perrin, Christophe, Naude, Claire, Cheaibi, Sélim, Fournier, Jean-Yves, Serre, Thierry, and Cadic, Ifsttar
- Subjects
SYSTEME DYNAMIQUE ,TRAITEMENT DES DONNEES ,CONDUITE NATURELLE ,DEUX-ROUES MOTORISES ,DEUX ROUES MOTORISE ,CONDUITE DU VEHICULE ,[MATH.MATH-DS] Mathematics [math]/Dynamical Systems [math.DS] ,DETECTION D'INCIDENT ,SOLLICITATION DYNAMIQUE ,DETECTION D'INCIDENTS ,COMPORTEMENT DYNAMIQUE - Abstract
Livrable L5 présentant les travaux du workpackage 5 du projet de recherche DYMOA+. L'objectif de la première partie de ce Work Package n°5 (WP5) est d'améliorer les critères de détection d'un incident pour un 2RM définis et utilisés dans le projet antérieur DYMOA. Les choix des variables et des seuils retenus pour ces critères semblent bien adaptés pour recueillir des évènements utiles pour le diagnostic d'infrastructure. En revanche ces critères s'avèrent moins efficaces pour différencier ces évènements d'incidents et surtout pour détecter les incidents "réels". Beaucoup trop de faux positifs sont enregistrés et de plus, des faux négatifs nous échappent certainement. Le but de ces travaux est donc d'améliorer ces critères ou d'en identifier de nouveaux, permettant si possible, de détecter des incidents "réels" et de les discerner des "fortes sollicitations". Pour cela il est probablement pertinent de combiner les variables et/ou de rajouter des notions de durée de dépassement de seuil. Une attention particulière est portée sur les variations de sollicitations, signes d'un effet de surprise, et annonciateurs de la présence d'une situation non souhaitée, plus proche de la définition d'un incident. Nous avons employé des méthodes utilisant des algorithmes d'apprentissage supervisé appliqués sur des jeux de données du projet DYMOA et d'autres données complémentaires acquises dans le cadre de ce projet DYMOA+. Ces méthodes donnent des résultats prometteurs qui restent à approfondir. La deuxième partie de ce WP5 présente l'exploitation complémentaire de données recueillies à la toute fin du projet DYMOA. Les données de conduite naturaliste de l'expérimentation DYMOA, acquises pendant une période de 18 mois avec 26 motos privées dans trois régions de France, ont été exploitées pour évaluer les niveaux de sollicitations réelles des 2RM. Il s'agissait plus particulièrement de données agrégées fournies pour l'ensemble des trajets, appelées « synthèses de parcours » et croisant les données accélérométriques et gyrométriques ainsi que les niveaux de vitesses. Cette étude vient compléter les résultats du livrable 3.3 de DYMOA, qui n'exploitait qu'une partie des données, concernant environ 3200 trajets. Sur 7500 trajets collectés, environ 6500 trajets ont pu être exploités pleinement, en correspondance avec les traces GPS qui permettent notamment de calculer les distances parcourues. La distance globale parcourue lors de ces trajets est d'environ 88000 km. Les résultats obtenus sur le jeu complet des données concernent en premier lieu les distributions globales, en temps passé, des accélérations longitudinale, latérale et verticale, et des vitesses de rotation tangage, roulis et lacet et de la vitesse, puis les valeurs extrêmes atteintes au moins une fois par les motocyclistes pour ces mêmes paramètres. La variabilité des comportements est ensuite illustrée allant d'une conduite souple à une conduite sportive. Les motocyclistes subissent rarement des niveaux élevés de sollicitations dynamiques. En accélération et décélération notamment, ils ne dépassent +-4 m/s² que 0,5% du temps. En ce qui concerne les virages, leur vitesse de roulis ne dépasse 20°/s que 0,8% du temps et leur vitesse de lacet que 2,1% du temps. Si l'on exclut le temps passé à l'arrêt ou à très faible vitesse (moins de 5 km/h), les motocyclistes passent 80 % de leur temps en dessous de 90 km/h et 3,2 % du temps au-dessus de 130 km/h, avec seulement 0,3 % du temps au-dessus de 150 km/h. Le comportement est très variable d'un motocycliste à l'autre, même sur les mêmes itinéraires. Ces données permettent de caractériser la dynamique des motos et de discriminer les différents comportements des motards.
- Published
- 2022
23. ENSEIGNEUR ET MAÎTRE : HEIDEGGER PÉDAGOGUE
- Author
-
Perrin, Christophe
- Published
- 2009
- Full Text
- View/download PDF
24. Pleomorphic Onychomatricoma: A Mimicker of Malignancy
- Author
-
Perrin, Christophe, primary and Ambrosetti, Damien, additional
- Published
- 2022
- Full Text
- View/download PDF
25. Microvascular injuries, secondary edema, and inconsistencies in lung vascularization between affected and nonaffected pulmonary segments of non-critically ill hospitalized COVID-19 patients presenting with clinical deterioration
- Author
-
Maincent, Cécile, primary, Perrin, Christophe, additional, Chironi, Gilles, additional, Baqué-Juston, Marie., additional, Berthier, Frédéric, additional, Paulmier, Benoît, additional, Hugonnet, Florent, additional, Dittlot, Claire, additional, Farhad, Ryan Lukas., additional, Renvoise, Julien, additional, Serrano, Benjamin, additional, Nataf, Valérie, additional, Mocquot, François, additional, Keita-Perse, Olivia, additional, Claessens, Yann-Erik, additional, and Faraggi, Marc, additional
- Published
- 2022
- Full Text
- View/download PDF
26. Tumoural thrombosis extended into the right atrium revealed by 18F-flurodeoxyglucose positron emission tomography/computed tomography
- Author
-
Girard, Antoine, primary, Perrin, Christophe, additional, Lavoué, Vincent, additional, Donal, Erwan, additional, and Palard-Novello, Xavier, additional
- Published
- 2021
- Full Text
- View/download PDF
27. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
- Author
-
Annonay, Mylène, primary, Gauquelin, Lisa, additional, Geiss, Romain, additional, Ung, Mony, additional, Cristol-Dalstein, Laurence, additional, Mouret-Reynier, Marie-Ange, additional, Goncalves, Anthony, additional, Abadie-Lacourtoisie, Sophie, additional, Francois, Eric, additional, Perrin, Christophe, additional, Le Fel, Johan, additional, Lorgis, Véronique, additional, Servent, Véronique, additional, Uwer, Lionel, additional, Jouannaud, Christelle, additional, Leheurteur, Marianne, additional, Joly, Florence, additional, Campion, Loic, additional, Courtinard, Coralie, additional, Villacroux, Olivier, additional, Petit, Thierry, additional, Soubeyran, Pierre, additional, Terret, Catherine, additional, Bellera, Carine, additional, Brain, Etienne, additional, and Delaloge, Suzette, additional
- Published
- 2021
- Full Text
- View/download PDF
28. Self-Illusion and Medical Expertise in the Era of COVID-19
- Author
-
Claessens, Arthur, primary, Keita-Perse, Olivia, additional, Berthier, Frédéric, additional, Raude, Jocelyn, additional, Chironi, Gilles, additional, Faraggi, Marc, additional, Rousseau, Gildas, additional, Chaillou-Opitz, Sylvie, additional, Renard, Hervé, additional, Aubin, Valérie, additional, Mercier, Bertrand, additional, Pathak, Atul, additional, Perrin, Christophe, additional, and Claessens, Yann-Erick, additional
- Published
- 2021
- Full Text
- View/download PDF
29. Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer
- Author
-
Modi, Shanu, primary, Saura, Cristina, additional, Yamashita, Toshinari, additional, Park, Yeon Hee, additional, Kim, Sung-Bae, additional, Tamura, Kenji, additional, Andre, Fabrice, additional, Iwata, Hiroji, additional, Ito, Yoshinori, additional, Tsurutani, Junji, additional, Sohn, Joohyuk, additional, Denduluri, Neelima, additional, Perrin, Christophe, additional, Aogi, Kenjiro, additional, Tokunaga, Eriko, additional, Im, Seock-Ah, additional, Lee, Keun Seok, additional, Hurvitz, Sara A, additional, Cortes, Javier, additional, Lee, Caleb, additional, Liu, Yali, additional, Zhang, Lin, additional, Shahidi, Javad, additional, Yver, Antoine, additional, Baselga, Jose, additional, and Krop, Ian E, additional
- Published
- 2021
- Full Text
- View/download PDF
30. Gilets airbags pour motocyclistes : analyse d'accidents et crash-tests
- Author
-
Serre, Thierry, MASSON, Catherine, LLARI, Maxime, CANU, Bastien, PY, Max, Perrin, Christophe, Laboratoire Mécanismes d'Accidents (IFSTTAR/TS2/LMA), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR), Laboratoire de Biomécanique Appliquée (LBA UMR T24), Aix Marseille Université (AMU)-Université Gustave Eiffel, and Cadic, Ifsttar
- Subjects
ACCIDENT ,EXPERIMENTATION BIOMECANIQUE ,SYSTEME DE SECURITE PASSIVE ,VITESSE ,ACCIDENTOLOGIE ,SECURITE PASSIVE ,AIRBAG ,MOTOCYCLISTE ,[INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation ,ACCIDENTS ,BIOMECANIQUE ,RECONSTITUTION D&apos ,DEUX-ROUES MOTORISES ,DEUX ROUES MOTORISE ,RECUEIL DE DONNEES ,COLLISION FRONTALE ,ENQUETE SUR LE LIEU DE L&apos ,[INFO.INFO-MO] Computer Science [cs]/Modeling and Simulation ,GILETS AIRBAG - Abstract
Colloque COSMOS - Connaissances Scientifiques sur les Motocycles, Marne-la-Vallée, FRANCE, 04-/11/2019 - 05/11/2019; Objectifs : Il existe aujourd'hui sur le marché différents modèles de gilets airbags qui permettent d'améliorer la protection des usagers de deux-roues motorisés (2RM). Ils sont conçus sur trois principes de déclenchement: « filaire » (un câble fixé au gilet et au 2RM se détache lors de l'éjection du motocycliste et déclenche le gonflage), « radio » (les capteurs placés sur le 2RM détectent la chute ou le choc et lancent le gonflage) et « autonome » (les capteurs sont intégrés dans le gilet). L'objectif de cette étude était d'évaluer la protection apportée au motocycliste par le port de tels gilets en essayant notamment d'identifier jusqu'à quelle vitesse d'impact ces gilets sont capables de protéger l'individu. Méthode : L'approche adoptée combine une analyse de terrain couplée à des reconstructions numériques et des expérimentations biomécaniques en laboratoire. Concernant l'analyse de terrain, l'objectif était de recueillir des données sur des accidents réels d'usagers de 2RM équipés de gilets airbag puis de les analyser en détail afin d'en dégager des conclusions sur leurs effets protecteurs. L'étude biomécanique s'est attachée à réaliser quatre essais expérimentaux de chocs (crash-tests) avec des gilets airbags de marques différentes. Ces essais consistent à reproduire un impact frontal pour le motocycliste contre une voiture placée perpendiculairement à la trajectoire du 2RM. La vitesse de la moto est d'environ 40 km/h et l'impact sur le véhicule se situe sur son côté latéral au niveau du pied milieu. Le temps de détection, le temps de gonflage et la durée de gonflage de chaque type de gilet sont évalués ainsi que les pressions à droite et à gauche du gilet. Les essais sont réalisés avec des corps donnés à la science qui sont préalablement équipés de capteurs accélérométriques. Résultats : L'analyse terrain a permis le recueil d'une trentaine d'accidents et montre que la majorité des accidentés portant un gilet airbag considère qu'il leur a évité des lésions. Ces cas sont principalement des chutes avec glissade mais peu avec des impacts directs contre un obstacle. Des reconstructions numériques d'accidents ont montré qu'une chute à 60 km/h ou un impact à 40km/h peuvent provoquer des lésions graves au tronc même avec le port du gilet airbag. Les essais crash-test montrent une différence notable entre les gilets filaires et les déclenchements radios. Les deuxièmes ayant une capacité à détecter le choc bien plus tôt et à se gonfler plus rapidement afin d'être opérationnel lors du choc du motocycliste contre l'obstacle. Il est à noter également des différences de pressions dans les gilets testés qui peuvent s'interpréter par une protection offerte légèrement différente suivant les produits. En effet, pour certains gilets cela peut se traduire par une tendance à plutôt absorber de l'énergie alors que d'autres produits auraient tendance à répartir l'effort appliqué. Conclusion : Cette recherche a permis une évaluation réelle de l'efficacité protectrice de plusieurs gilets airbags commercialisés de nos jours. Il en ressort que le gilet airbag est globalement bien perçu par les usagers et que la plupart de ceux qui ont eu un accident relèvent son effet protecteur. Toutefois, des cas ont été recueillis où les configurations de choc montrent que les gilets ont un effet protecteur limité aussi bien en cas de choc contre un obstacle qu'en cas de chute puis glissade. Des essais crash-test ont montré une différence notable entre les gilets filaires et les déclenchements radios notamment en termes de temps de déclenchement. Il apparaît donc important de bien évaluer cette valeur dans le but de déterminer les produits les plus efficaces. D'une manière générale, le gilet airbag assure, pour l'ensemble du tronc, le même niveau de protection qu'un casque pour la tête.
- Published
- 2019
31. Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study
- Author
-
HEUDEL, PIERRE, primary, DELALOGE, SUZETTE, additional, PARENT, DAMIEN, additional, MADRANGES, NICOLAS, additional, LEVY, CHRISTELLE, additional, DALENC, FLORENCE, additional, BRAIN, ETIENNE, additional, UWER, LIONEL, additional, D'HONDT, VERONIQUE, additional, AUGEREAU, PAULE, additional, MAILLIEZ, AUDREY, additional, PERRIN, CHRISTOPHE, additional, FRENEL, JEAN-SEBASTIEN, additional, SABLIN, MARIE-PAULE, additional, MOURET-REYNIER, MARIE-ANGE, additional, VERMEULIN, THOMAS, additional, EYMARD, JEAN-CHRISTOPHE, additional, PETIT, THIERRY, additional, FERRERO, JEAN-MARC, additional, ILIE, SILVIA, additional, GONCALVES, ANTHONY, additional, CHENUC, GAËLLE, additional, ROBAIN, MATHIEU, additional, SIMON, GAËTANE, additional, and PEROL, DAVID, additional
- Published
- 2020
- Full Text
- View/download PDF
32. Europe should lead in coordinated procurement of quality-assured medicines for programmes in low-income and middle-income countries
- Author
-
Perrin, Christophe, primary, Cloez, Sandrine, additional, Dujardin, Catherine, additional, and Ravinetto, Raffaella, additional
- Published
- 2020
- Full Text
- View/download PDF
33. Some Notes on the Phenomenon of Solitude
- Author
-
Perrin, Christophe, primary
- Published
- 2020
- Full Text
- View/download PDF
34. Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)
- Author
-
Krop, Ian E, primary, Saura, Cristina, additional, Yamashita, Toshinari, additional, Park, Yeon Hee, additional, Kim, Sung-Bae, additional, Tamura, Kenji, additional, André, Fabrice, additional, Iwata, Hiroji, additional, Ito, Yoshinori, additional, Tsurutani, Junji, additional, Sohn, Joohyuk, additional, Denduluri, Neelima, additional, Perrin, Christophe, additional, Aogi, Kenjiro, additional, Tokunaga, Eriko, additional, Im, Seock-Ah, additional, Lee, Keun Seok, additional, Hurvitz, Sara, additional, Cortes, Javier, additional, Lee, Caleb, additional, Chen, Shuquan, additional, Zhang, Lin, additional, Shahidi, Javad, additional, Yver, Antoine, additional, and Modi, Shanu, additional
- Published
- 2020
- Full Text
- View/download PDF
35. LA VIE EST UNE RÉUSSITE: PETITE DIALECTIQUE DE L'ÉCHEC.
- Author
-
PERRIN, Christophe
- Subjects
LOGIC ,VIRTUES ,HOPE ,SENSES ,VIRTUE ,SUCCESS - Abstract
Copyright of Phainomena is the property of Phenomenological Society of Ljubljana and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
36. Airbag Jacket for Motorcyclists: Evaluation of Real Effectiveness
- Author
-
Serre, Thierry, Masson, Catherine, Llari, Maxime, Canu, Bastien, Py, Max, Perrin, Christophe, Laboratoire Mécanismes d'Accidents (IFSTTAR/TS2/LMA), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR), Laboratoire de Biomécanique Appliquée (LBA UMR T24), Aix Marseille Université (AMU)-Université Gustave Eiffel, and Cadic, Ifsttar
- Subjects
ACCIDENT ,COLLISION ,ACCIDENTOLOGIE ,AIRBAG ,MOTOCYCLISTE ,BIOMECHANICS ,[INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation ,BIOMECANIQUE ,POWERED TWO WHEELERS ,DEUX ROUES MOTORISE ,RECUEIL DE DONNEES ,SECURITE ROUTIERE ,AIRBAG JACKET ,ENQUETE SUR LE LIEU DE L&apos ,MOTORCYCLIST SAFETY ,[INFO.INFO-MO] Computer Science [cs]/Modeling and Simulation - Abstract
IRCOBI 2019, International Conference on the Biomechanics of Injury, Florence, ITALIE, 11-/09/2019 - 13/09/2019; This paper aims to evaluate the level of protection offered by airbag jackets for Powered Two Wheeler users. This research is based on a double approach which combines real accident data collected with a field survey and experimental data obtained in laboratory. The accident study shows that the airbag is globally well perceived by their users who highlight their protective effects. But these cases have mainly fallen from the motorcycles at low speeds and less direct impacts against an obstacle. However, some specific cases show that a direct impact at 40km/h or falling at 60km/h with an airbag jackets cannot avoid serious injuries on the trunk (AIS3+). Experimental tests consist on performing crash-tests with PMHS motorcyclists thrown at about 40km/h against passenger cars. Results show differences between the type of airbag jacket in terms of pressure and trigger time. The airbag jackets seem to offer limited protection from a threshold speed which can be estimated to an impact around to 30-40km/h but these speeds differ with the impact configuration.
- Published
- 2019
37. Real Use of the Dynamic Capacities of Motorcycles
- Author
-
Naude, Claire, Serre, Thierry, Perrin, Christophe, Cornen, Romane, Laboratoire Mécanismes d'Accidents (IFSTTAR/TS2/LMA), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR), RP1-J13164, DYMOA, and Cadic, Ifsttar
- Subjects
[INFO.INFO-DB]Computer Science [cs]/Databases [cs.DB] ,PRISE DE RISQUE ,ENREGISTREMENT DES DONNEES ,COLLISION ,ACCIDENT DE LA ROUTE ,COMPORTEMENT DU CONDUCTEUR ,ACCIDENTOLOGIE ,MOTOCYCLISTE ,COMPORTEMENT DYNAMIQUE ,VEHICLE DYNAMICS ,DEUX ROUES MOTORISE ,RECUEIL DE DONNEES ,SECURITE ROUTIERE ,RIDER BEHAVIOR ,[INFO.INFO-DB] Computer Science [cs]/Databases [cs.DB] ,ROAD SAFETY ,MOTORCYCLE - Abstract
FAST-zero-19, 5th International Symposium on Future Active Safety Technology toward Zero Accidents, Blacksburg, ETATS-UNIS, 09-/09/2019 - 11/09/2019; Motorcycle crashes are on the increase in most occidental countries whereas there is a decrease in crashes involving cars. Motorcyclists are more likely to be injured or killed than car occupants. It can be explained by their vulnerability on the road but also by their riskier behavior. There is a need to extend the knowledge on Power Two-Wheeler (PTW) mobility and crash mechanisms. This paper aims to explore the real use of PTW's dynamic capacities by the riders in a French Naturalistic Riding Study with 26 equipped motorcycles. The results concern 36500 km traveled during one year. Data used are syntheses aggregating the time spent in every combination of longitudinal acceleration and roll or yaw rate, included the speed information. The motorcyclists endure rarely high levels of dynamic demands: in acceleration and deceleration they exceed +-4 m/s² only 0.2% of the time and in lateral their roll rate exceeds 20°/s only 0.8% of the time and their yaw rate 1.4% of the time. This kind of data also allows discriminating different behaviors between a sporty and a smoother way of riding a motorcycle.
- Published
- 2019
38. Études détaillées d'accidents impliquant des véhicules utilitaires légers
- Author
-
Serre, Thierry, Perrin, Christophe, DUBOIS-LOUNIS, Maxime, Naude, Claire, Cadic, Ifsttar, Laboratoire Mécanismes d'Accidents (IFSTTAR/TS2/LMA), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR), and EDAVUL, Études Détaillées d'Accidents impliquant des Véhicules Utilitaires Légers
- Subjects
ACCIDENT ,[INFO.INFO-DB]Computer Science [cs]/Databases [cs.DB] ,ETUDE DETAILLEE D&apos ,VEHICULE UTILITAIRE LEGER - VUL ,ACCIDENT DE LA CIRCULATION ,VEHICULE UTILITAIRE LEGER ,ENQUETE SUR LE LIEU DE L&apos ,ACCIDENT DE LA ROUTE ,[INFO.INFO-DB] Computer Science [cs]/Databases [cs.DB] ,ACCIDENTOLOGIE - Abstract
Cet article rend compte de travaux réalisés en 2012-2013, qui visaient à établir les principales caractéristiques des accidents impliquant des véhicules utilitaires légers (VUL) à partir de cas d'accidents recueillis dans la base des Études détaillées d'accidents (EDA) constituée au laboratoire Mécanismes d'accidents de l'IFSTTAR. Cette recherche a donné lieu à une communication en anglais (Thierry Serre, Christophe Perrin, Maxime Dubois-Lounis, Claire Naude, 2014, In-depth study of accidents involving light goods vehicles, ESAR 2014, 6th International Conference: Expert Symposium on Accident Research, June 2014, Hanover, Germany ; https://hal.archives-ouvertes.fr/hal-01207835), mais n'avait pas encore fait l'objet d'une diffusion auprès du public francophone. Le principal objectif était d'investiguer en profondeur les processus de ces accidents pour identifier les facteurs spécifiques aux différents types de VUL. Cela a nécessité en particulier de reconstruire la cinématique de ces accidents pour calculer les vitesses moyennes d'impact, et d'étudier les problèmes de compatibilité entre les VUL et les véhicules antagonistes. Un autre objectif consistait à définir les différences entre les types de VUL et l'influence de la configuration du VUL dans l'accident (charge...). Le travail est basé sur les données des études détaillées d'accidents et leur analyse clinique. L'échantillon retenu inclut les VUL d'un poids total autorisé en charge (PTAC) inférieur à 3,5 tonnes, soit 88 accidents impliquant 90 VUL. À partir des dossiers EDA, comportant de nombreux relevés d'information et une analyse approfondie de chaque cas, la première étape a été de créer un fichier de codage spécifique comprenant les principales caractéristiques des accidents de VUL avec des variables permettant notamment d'identifier les problèmes de sécurité, de maintenance, de chargement, de conception du VUL. Les variables les plus importantes concernaient : Les conditions générales de l'accident : situation météo, type de lieu, nombre de personnes blessées, etc. Les caractéristiques du véhicule : kilométrage, type, état général, volume et charge utiles, présence de l'ABS (antiblocage des roues), description des éléments essentiels de la sécurité primaire relative à la survenue de l'accident, taille des pneus, indice de charge de chaque pneu (relevé et recommandé par le constructeur), etc. Les éléments relatifs à la sécurité secondaire : type de choc, vitesses d'impact, présence d'airbags, fixation et disposition du chargement ainsi que son implication dans l'accident. Les principaux résultats de cette recherche sont les suivants : La moitié des VUL de l'échantillon sont des modèles « légers » tels que Renault Kangoo, Peugeot Partner. Les VUL sont moins souvent impliqués dans des pertes de contrôle, et plus fréquemment impliqués dans des accidents en intersection, probablement en raison de problèmes de perception des autres usagers chez les conducteurs de VUL. Peu de défauts techniques ont été relevés et presque uniquement des défauts de pression ou d'indices de charge des pneumatiques ; le contrôle de pression des pneus devrait être renforcé. Le déplacement de charges ne joue généralement pas un rôle déterminant dans les accidents en partie grâce à la présence de parois séparatrices. Sur l'échantillon étudié (véhicules fabriqués avant 2012), les VUL sont peu équipés de systèmes de sécurité active en particulier de radar ou de caméra de recul, bien que leur visibilité vers l'arrière soit très faible ; de même le taux d'équipement en systèmes de sécurité passive est faible (airbags...). Peu de conducteurs de VUL mettent la ceinture de sécurité. Il apparaît nécessaire d'encourager le port de la ceinture par tous les moyens : alerte sonore, communication, campagnes de sensibilisation et de répression. Les chocs sont principalement frontaux pour les VUL. Les vitesses d'impact des VUL sont équivalentes à celles des autres véhicules. L'agressivité des VUL semble poser problème et la compatibilité véhicule-véhicule devrait être mieux prise en compte.
- Published
- 2019
39. Framework for patient-ventilator asynchrony during long term non-invasive ventilation
- Author
-
Gonzalez-Bermejo, Jesus, Janssens, Jean-Paul, Rabec, Claudio, Perrin, Christophe, Lofaso, Frédéric, Langevin, Bruno, Carlucci, Annalisa, Lujan, Manel, SomnoNIV group, Neurophysiologie Respiratoire Expérimentale et Clinique (UMRS 1158), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de Pneumologie et Réanimation Médicale [CHU Pitié-Salpêtrière] (Département ' R3S '), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Geneva University Hospital (HUG), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Princesse Grace [Monaco], Service de physiologie et d'explorations fonctionnelles [CHU Raymond-Poincaré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Raymond Poincaré [AP-HP], Hôpital Raymond Poincaré [AP-HP], Service de réanimation [CH Alès-Cévennes], Centre Hospitalier Alès-Cévennes, Pulmonary Rehabilitation [Pavia, Italy], Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS)-Istituti Clinici Scientifici [Pavia, Italy], Universitat Autònoma de Barcelona (UAB), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Gestionnaire, Hal Sorbonne Université, Neurophysiologie Respiratoire Expérimentale et Clinique, and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
obstructive sleep apnoea ,Polysomnography ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,central sleep apnea ,Physiologic/methods ,Hypercapnia ,Computer-Assisted ,0302 clinical medicine ,polysomnography ,Time windows ,030212 general & internal medicine ,Patient ventilator asynchrony ,ddc:616 ,medicine.diagnostic_test ,integumentary system ,non-invasive ventilation ,Signal Processing, Computer-Assisted ,Limiting ,3. Good health ,Asynchrony (computer programming) ,Noninvasive Ventilation/adverse effects/methods ,Respiratory Physiological Phenomena ,Cardiology ,asynchrony ,Respiratory Insufficiency ,Algorithms ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Central sleep apnea ,home ventilators ,monitoring ,sleep-disordered breathing ,Monitoring ,Respiratory Insufficiency/physiopathology/therapy ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Hypercapnia/therapy ,Positive pressure ventilation ,Monitoring, Physiologic ,Noninvasive Ventilation ,business.industry ,medicine.disease ,Term (time) ,030228 respiratory system ,Signal Processing ,[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,business - Abstract
International audience; Episodes of patient-ventilator asynchrony (PVA) occur during acute and chronic non-invasive positive pressure ventilation (NIV). In long-term NIV, description and quantification of PVA is not standardised, thus limiting assessment of its clinical impact. The present report provides a framework for a systematic analysis of polygraphic recordings of patients under NIV for the detection and classification of PVA validated by bench testing. The algorithm described uses two different time windows: rate asynchrony and intracycle asynchrony. This approach should facilitate further studies on prevalence and clinical impact of PVA in long-term NIV.
- Published
- 2019
40. Involvement of Cholecystokinin 2 Receptor in Food Intake Regulation: Hyperphagia and Increased Fat Deposition in Cholecystokinin 2 Receptor-Deficient Mice
- Author
-
Clerc, Pascal, Constans, Maria Gràcia Coll, Lulka, Hubert, Broussaud, Stéphanie, Guigné, Charlotte, Leung-Theung-Long, Stéphane, Perrin, Christophe, Knauf, Claude, Carpéné, Christian, Pénicaud, Luc, Seva, Catherine, Burcelin, Rémy, Valet, Philippe, Fourmy, Daniel, and Dufresne, Marlène
- Published
- 2007
41. Liver Adenosine Monophosphate-Activated Kinase-α2 Catalytic Subunit Is a Key Target for the Control of Hepatic Glucose Production by Adiponectin and Leptin But Not Insulin
- Author
-
Andreelli, Fabrizio, Foretz, Marc, Knauf, Claude, Cani, Patrice D., Perrin, Christophe, Iglesias, Miguel A., Pillot, Bruno, Bado, André, Tronche, François, Mithieux, Gilles, Vaulont, Sophie, Burcelin, Rémy, and Viollet, Benoit
- Published
- 2006
42. Brain glucagon-like peptide–1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage
- Author
-
Knauf, Claude, Cani, Patrice D., Perrin, Christophe, Iglesias, Miguel A., Maury, Jean François, Bernard, Elodie, Benhamed, Fadilha, Grémeaux, Thierry, Drucker, Daniel J., Kahn, C. Ronald, Girard, Jean, Tanti, Jean François, Delzenne, Nathalie M., Postic, Catherine, and Burcelin, Rémy
- Published
- 2005
43. Extralobar sequestration with anomalous pulmonary artery return or patent ductus arteriosus?
- Author
-
Pop, Daniel, Venissac, Nicolas, Perrin, Christophe, Leo, Francesco, Padovani, Bernard, and Mouroux, Jéròme
- Published
- 2005
44. The Link Between Nutritional Status and Insulin Sensitivity Is Dependent on the Adipocyte-Specific Peroxisome Proliferator–Activated Receptor-γ2 Isoform
- Author
-
Medina-Gomez, Gema, Virtue, Sam, Lelliott, Christopher, Boiani, Romina, Campbell, Mark, Christodoulides, Constantinos, Perrin, Christophe, Jimenez-Linan, Mercedes, Blount, Margaret, Dixon, John, Zahn, Dirk, Thresher, Rosemary R., Aparicio, Sam, Carlton, Mark, Colledge, William H., Kettunen, Mikko I., Seppänen-Laakso, Tuulikki, Sethi, Jaswinder K., OʼRahilly, Stephen, Brindle, Kevin, Cinti, Saverio, Oresic, Matej, Burcelin, Remy, and Vidal-Puig, Antonio
- Published
- 2005
45. Intracerebroventricular Infusion of Glucose, Insulin, and the Adenosine Monophosphate-Activated Kinase Activator, 5-Aminoimidazole-4-Carboxamide-1-β-d-Ribofuranoside, Controls Muscle Glycogen Synthesis
- Author
-
Perrin, Christophe, Knauf, Claude, and Burcelin, Rémy
- Published
- 2004
46. Partial Gene Deletion of Endothelial Nitric Oxide Synthase Predisposes to Exaggerated High-Fat Diet-Induced Insulin Resistance and Arterial Hypertension
- Author
-
Cook, Stéphane, Hugli, Olivier, Egli, Marc, Ménard, Barbara, Thalmann, Sébastien, Sartori, Claudio, Perrin, Christophe, Nicod, Pascal, Thorens, Bernard, Vollenweider, Peter, Scherrer, Urs, and Burcelin, Rémy
- Published
- 2004
47. The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator--activated receptor-[gamma]2 isoform
- Author
-
Medina-Gomez, Gema, Virtue, Sam, Lelliott, Christopher, Boiani, Romina, Campbell, Mark, Christodoulides, Constantinos, Perrin, Christophe, Jimenez-Linan, Mercedes, Blount, Margaret, Dixon, John, Zahn, Dirk, Thresher, Rosemary R., Aparicio, Sam, Carlton, Mark, Colledge, William H., Kettunen, Mikko I., Seppanen-Laakso, Tuulikki, Sethi, Jaswinder K., O'Rahilly, Stephen, Brindle, Kevin, Cinti, Saverio, Oresic, Matej, Burcelin, Remy, and Vidal-Puig, Antonio
- Subjects
Obesity -- Research ,Peroxisomes ,Insulin ,Fat cells ,Health - Abstract
The nuclear receptor peroxisome proliferator-activated receptor-[gamma] (PPAR[gamma]) is critically required for adipogenesis. PPAR[gamma] exists as two isoforms, [gamma]1 and [gamma]2. PPAR[gamma]2 is the more potent adipogenic isoform in vitro and is normally restricted to adipose tissues, where it is regulated more by nutritional state than PPAR[gamma]1. To elucidate the relevance of the PPAR[gamma]2 in vivo, we generated a mouse model in which the PPAR[gamma]2 isoform was specifically disrupted. Despite similar weight, body composition, food intake, energy expenditure, and adipose tissue morphology, male mice lacking the [gamma]2 isoform were more insulin resistant than wild-type animals when fed a regular diet. These results indicate that insulin resistance associated with ablation of PPAR[gamma]2 is not the result of lipodystrophy and suggests a specific role for PPAR[gamma]2 in maintaining insulin sensitivity independently of its effects on adipogenesis. Furthermore, PPAR[gamma]2 knockout mice fed a high-fat diet did not become more insulin resistant than those on a normal diet, despite a marked increase in their mean adipocyte cell size. These findings suggest that PPAR[gamma]2 is required for the maintenance of normal insulin sensitivity in mice but also raises the intriguing notion that PPAR[gamma]2 may be necessary for the adverse effects of a high-fat diet on carbohydrate metabolism., Peroxisome proliferator-activated receptor-[gamma] (PPAR[gamma]) plays a central role in adipogenesis and insulin sensitivity. PPAR[gamma] is expressed as two isoforms, PPAR[gamma]1 and PPAR[gamma]2, which differ only in that PPAR[gamma]2 has 30 [...]
- Published
- 2005
48. GLUT4, AMP kinase, but not the insulin receptor, are required for hepatoportal glucose sensor-stimulated muscle glucose utilization
- Author
-
Burcelin, Rémy, Crivelli, Valerie, Perrin, Christophe, Da Costa, Anabela, Mu, James, Kahn, Barbara B., Birnbaum, Morris J., Kahn, C. Ronald, Vollenweider, Peter, and Thorens, Bernard
- Published
- 2003
49. Perineurioma: A Tendon Sheath Fibroma-like Variant in a Distal Subungual Location
- Author
-
Baran, Robert and Perrin, Christophe
- Published
- 2003
50. The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity
- Author
-
Viollet, Benoit, Andreelli, Fabrizio, Jørgensen, Sebastian B., Perrin, Christophe, Geloen, Alain, Flamez, Daisy, Mu, James, Lenzner, Claudia, Baud, Olivier, Bennoun, Myriam, Gomas, Emmanuel, Nicolas, Gaël, Wojtaszewski, Jørgen F.P., Kahn, Axel, Carling, David, Schuit, Frans C., Birnbaum, Morris J., Richter, Erik A., Burcelin, Rémy, and Vaulont, Sophie
- Published
- 2003
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.